©Reuters.
Ceras Inc. (NASDAQ:) Chief Financial Officer Kevin Dennis Green recently sold a total of $84,881 worth of company stock, according to the company's most recent Form 4 filing with the Securities and Exchange Commission. The transactions took place on March 13th and March 14th, with shares sold at prices ranging from $1.9744 to $2.0153 per share.
On March 13, Green sold 21,058 shares of Cerus Corp common stock at an average price of approximately $2.0153 per share. The next day, he sold an additional 21,497 shares at an average price of $1.9744 per share. These sales were executed in multiple transactions at various prices within the stated range.
The sale was part of a pre-arranged plan under Rule 10b5-1, which allows company insiders to make advance plans to sell stock at a time when they do not possess material non-public information. It can be erected. This plan was introduced to cover statutory withholding obligations and related brokerage fees associated with the vesting of certain restricted stock units. It's important to note that these transactions do not necessarily indicate a lack of confidence in the company by management. Rather, they are often part of a regular financial planning strategy.
Prior to these transactions, Green acquired 21,666 shares through vesting of restricted stock units, as shown in the same Form 4 filing. These units represent a contingent right to receive Cerus Corp. common stock and are part of an executive compensation package that vests over a period of time.
As a result of these transactions, Green's direct ownership in Cerus Corp was adjusted to 618,750 shares of common stock.
Investors often monitor insider buying and selling because they can learn about management's views on a company's future prospects. However, it is also important to consider the broader context in which these transactions occur, such as compensation plans and personal financial management.
Cerus Corp. is based in Concord, California and specializes in the development and commercialization of surgical and medical instruments and devices. The company focuses on products that can improve blood safety and provide innovative solutions for the medical field.
Investment Pro Insights
Cerus Corp (NASDAQ:CERS) has experienced significant share price movement recently, which is reflected in InvestingPro's real-time indicators. The company's market capitalization is currently approximately $358.94 million. Despite the volatility, the company's current assets are reported to be higher than its short-term debt, suggesting some financial stability in the face of market pressures.
As of the trailing twelve months ending in Q4 2023, Cerus Corp's current price-to-book ratio is relatively high at 6.82, which is a metric that compares the company's market value to book value. This may indicate that the stock is being traded at a premium. Convert to net asset value. Additionally, the adjusted P/E ratio for the same period was -10.2, which may suggest that investors are expecting future growth, even though the company did not make a profit in the past 12 months. There is a gender.
According to InvestingPro Tips, analysts do not expect Ceras Corp. to make a profit this year, and the stock's performance has been weak over the past month, with the stock's total return for the month being -17.15%. There is. Additionally, the company does not pay dividends to shareholders, which is an important consideration for income-oriented investors.
If you want to learn more about Cerus Corp's financials and stock performance, we have additional InvestingPro Tips for you. Investors can access these tips and a wealth of other detailed financial information by visiting https://www.investing.com/pro/CERS.Use coupon code pro news 24 Get an extra 10% off annual or biennial Pro and Pro+ subscriptions, and get even more insights to help you make investment decisions. With the latest data and analysis at your fingertips, you can better assess the potential risks and rewards associated with Cerus Corp stock.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
